Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rezolute’s SEC documents are packed with clinical trial data, complex R&D accounting, and frequent equity offerings—details that can overwhelm even seasoned biotech investors. If you have ever searched “Rezolute SEC filings explained simply” or wondered how Phase 2 updates hidden in an 8-K might affect cash-runway projections, this page ends the chase.
Stock Titan’s AI-powered analysis turns 200-page reports into clear takeaways. Get instant context for every Rezolute quarterly earnings report 10-Q filing, see cash burn trends visualized, and read side-by-side comparisons of trial milestones from successive 10-Ks. Real-time alerts surface Rezolute Form 4 insider transactions—so you see executive stock moves minutes after they hit EDGAR. Our platform also links each Rezolute 8-K material events explained summary to the original disclosure, letting you trace headline trial data back to the exact page.
Looking for specifics? You’ll find:
- Rezolute annual report 10-K simplified—clinical pipeline tables, risk factors, and going-concern commentary distilled into plain English.
- Rezolute executive stock transactions Form 4 and insider trading Form 4 transactions displayed with trend graphs.
- Rezolute proxy statement executive compensation insights—compare R&D milestones to bonus targets in seconds.
Whether you need Rezolute earnings report filing analysis before your next model update or are simply understanding Rezolute SEC documents with AI, our comprehensive coverage keeps you ahead. All filings, all the time—streamlined so you can focus on what matters: evaluating the science and the story behind RZLT.
Rezolute, Inc. is asking shareholders to vote at the Annual Meeting on a slate of routine corporate matters including election of seven director nominees, ratification of Grant Thornton LLP as independent auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2021 Equity Incentive Compensation Plan to increase available shares from 14,450,000 to 21,950,000. The proxy materials will be delivered primarily via internet starting on or about
Rezolute, Inc. Schedule 13G summary: This filing reports that several affiliated entities and individuals associated with Invus and Avicenna disclosed beneficial ownership of Rezolute common stock. Invus Public Equities directly holds 4,171,401 shares (about 4.6% of the class) and Avicenna Life Sci Master Fund LP directly holds 698,599 shares (about 0.8%). Combined, Mr. Raymond Debbane is disclosed as beneficial owner of 4,870,000 shares, representing 5.4% of the 90,811,368 shares outstanding used in the calculation. The filing states the positions were not acquired to change control of the issuer and lists addresses and organizational citizenship for each reporting person.
Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.
The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.
Rezolute, Inc. (RZLT) Form 4 shows the company granted equity to its Chief Commercial Officer, Sunil Ratilal Karnawat. On 08/18/2025 Karnawat was awarded 25,000 restricted stock units that vest in four equal annual installments beginning 09/01/2026. The filing also reports an employee stock option grant to purchase 275,000 common shares at an exercise price of $6.55 per share, exercisable under a vesting schedule beginning one year after grant and completing monthly thereafter, with an expiration on 08/18/2035. Following the reported transactions, Karnawat directly beneficially owns 27,442 common shares and indirectly holds 8,000 shares in an IRA and 1,898 shares in an HSA. The Form 4 was signed by Karnawat on 08/27/2025.
Rezolute, Inc. (RZLT) Form 3 filed for Sunil Ratilal Karnawat reports initial beneficial ownership disclosures for an officer serving as Chief Commercial Officer. The filing shows 2,442 common shares held directly, plus 8,000 common shares held indirectly in an IRA and 1,898 common shares held indirectly in a Health Savings Account, for a total of 12,340 shares reported. The filing is signed and dated by the reporting person.
Rezolute, Inc. filed an Form 8-K reporting a material corporate event under Item 5.02: the election or appointment of a Chief Commercial Officer. The filing references a press release dated August 20, 2025 and is signed by Chief Executive Officer Nevan Charles Elam. The submission also includes standard cover and interactive data references for the Inline XBRL document and cites communications rules for solicitations and pre-commencement communications under the Securities Act and Exchange Act.
The filing provides notice of an executive appointment but does not disclose the appointee's name, compensation, start date, or other background details within the provided text. No financial tables, transactions, or earnings data are included in the excerpt supplied.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
